Advanced research on vasculogenic mimicry in cancer

Lili Qiao a, Ning Liang b, Jiandong Zhang b, *, Jian Xie c, Fengjun Liu b, Deguo Xu b, Xinshuang Yu b, Yuan Tian b

a Department of Oncology, Shandong University School of Medicine, Jinan, Shandong Pro, China
b Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong Pro, China
c Department of Oncology, Zhangqiu People’s Hospital, Jinan, Shandong Pro, China

Received: July 8, 2014; Accepted: October 20, 2014

Abstract

Vasculogenic mimicry (VM) is a brand-new tumour vascular paradigm independent of angiogenesis that describes the specific capacity of aggressive cancer cells to form vessel-like networks that provide adequate blood supply for tumour growth. A variety of molecule mechanisms and signal pathways participate in VM induction. Additionally, cancer stem cell and epithelial-mesenchymal transitions are also shown to be implicated in VM formation. As a unique perfusion way, VM is associated with tumour invasion, metastasis and poor cancer patient prognosis. Due to VM’s important effects on tumour progression, more VM-related strategies are being utilized for anticancer treatment. Here, with regard to the above aspects, we make a review of advanced research on VM in cancer.

Keywords: vasculogenic mimicry • molecular regulation • cancer stem cell • tumour-target therapy • prognosis • high aggressive tumour

Introduction

Tumour angiogenesis plays a significant role in tumour growth and metastasis, which was formerly considered the unique choice for tumour blood supply [1–4]. Further research has introduced a new channel pattern called ‘vasculogenic mimicry (VM)’, which describes the functional plasticity of aggressive cancer cells in expressing a multipotent, stem cell-like phenotype and forming extracellular matrix (ECM)-rich and patterned vessel-like networks in three-dimensional matrix. Human melanoma cells’ VM is initially characterized as showing that the tumour cells co-expressing endothelial and tumour markers could form vascular channel structures. This provides growing tumours with sufficient blood perfusion and at the same time promotes cancer metastasis and progression [5–7]. Besides human melanoma [8, 9], VM has been observed in other malignant tumours [10–12], including glioblastoma [13–16], gallbladder cancer [17, 18], ovarian cancer [19–21], lung cancer [22], hepatocellular cancer (HCC) [23], breast cancer [24], prostate cancer [14], osteosarcoma [25] and gastric cancer [26, 27]. More studies aimed to investigate VM’s formation mechanisms and signalling pathways (Fig. 1) [28], including some factors related to tumour cell migration, invasion and matrix remodelling, such as vascular endothelial-cadherin (VE-cadherin) [29, 30], epithelial cell kinase (EphA2) [10, 31, 32], phosphoinositide 3-kinase (PI3K), matrix metalloproteinase (MMPs), laminin 5 (Ln-5) γ2 chain [33–36], hypoxiainducible factor1-α (HIF-α) [37] and focal adhesion kinase (FAK) [38, 39]. However, the exact mechanisms

*Correspondence to: Jiandong ZHANG, M.D., Ph.D., Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University School of Medicine, No. 16766 Jingshi Road, Jinan, Shandong Pro, China. Tel.: 86-13583123486 E-mail: zhangjd165@sina.com

© 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

doi: 10.1111/jcm.12496
remain unclear. Additionally, a poor cancer patient clinical outcome was shown to be correlated with VA formation in malignant tumour tissues, and cancer patients with VM tended towards tumour metastasis and had a lower survival rate. VM may be an important target for anticancer therapy, so further studies are needed to improve cancer treatment.

Discovering VM

Malignant solid tumours need blood supply to promote growth and metastasis. In the past, angiogenesis, one type of neovascularization in embryo development, was regarded as the only form of supporting tumour blood supply. Angiogenesis was first used by British surgeon John Hunter in 1787 to describe blood vessel growth in reindeer antlers. In 1966, Warren first described angiogenesis in melanoma, and afterwards it was investigated in other tumours [40, 41]. Some studies suggested that angiogenesis was associated with malignant tumour growth and survival [42]. Anti-angiogenesis therapies targeting endothelial cells as a potential and promising treatment target have received much attention and investigation. Many anti-angiogenesis drugs have been used to prevent tumour growth and metastasis. However, the drugs’ effects on anticancer progression was restricted and unsatisfactory, which indicated that there may be other blood supply forms in tumour tissues besides angiogenesis. In 1999, Maniotis et al. [5] reported a highly patterned vessel-like channel structure in highly aggressive and metastatic human melanoma in which red-blood cells were detected. Interestingly, endothelial cells were not identified in these channels by light microscopy, transmission electron microscopy or immunohistochemical detection of endothelial cell markers such as Factor VIII-related antigen, CD34, CD31, Ulex and KDR (Fk-1). Subsequently, they found that this structure, different from angiogenesis, was comprised of a basement membrane and mainly lined by tumour cells. Melanosome and pre-melanosome were observed in these cells, rather than endothelial cells, showing positive periodic acid-schiff (PAS) and negative CD31 staining using PAS and CD31 staining methods. The vessel-like structures were called ‘VM’. The features of positive PAS and negative CD31 are regarded as the golden standard for tumour cell-lined VM. Generally, VM is divided into two distinctive types: tubular and patterned matrix types [16]. VM formation has been found in various highly aggressive tumours in humans, but it was not generated in poorly aggressive melanoma and normal melanocytes under the same culture conditions in vitro. Additionally, some researchers also confirmed that VM provides an important perfusion pathway for malignant tumours through sufficient blood and nutrition supply, playing a significant role in tumour growth.

Vasculogenic mimicry is linked with numerous tumour malignancies, including invasion and metastasis [5, 43, 44]. Relevant research verified that there exists a junction in tumour tissues between tumour-lined vascular channels and endothelial-lined blood vessels [45–47]. Through this structure, tumour cells lining the inner network channel surface are directly exposed to the blood, significantly increasing transfer opportunities.

Generally, VM characteristics can be summarized as follows: (i) positive PAS and negative CD31 straining; (ii) the channel is lined by
tumour cells rather than endothelial cells; (iii) the expression of a multpotent, stem cell-like phenotype; (iv) ECM remodelling and (v) VM has connection with the tumour microcirculation system, providing blood for tumour growth. Major VM discoveries are illustrated in Table 1.

**Tumour VM formation mechanisms**

The roles of major adhesion molecules and other factors in VM formation are shown in Table 2.

**Molecule mechanisms involved in VM formation**

**PI3K/Akt, MMPs and Ln-5 β2 chain**

PI3K is a lipid kinase that acts through the phosphorylation process of its substrates, mainly including phosphatidylinositol or its derivatives. The PI3K signal pathway has been shown to be imperative in normal cell processes like proliferation, differentiation, survival, metabolism and motility [48]. Akt, also known as protein kinase B (PKB), is a serine/threonine PK that plays an integral role in the PI3K metabolism and motility [48]. Akt, also known as protein kinase B (PKB), is a serine/threonine PK that plays an integral role in the PI3K signal pathway. PI3K’s products after activation, including PI-3,4-P2 and PI-3,4,5-P3, could combine with Akt’s pleckstrin homology (PH) domain. This leads to Akt’s translocation from the cytoplasm to the cell membrane and its conformational change, further promoting its activation. It has been confirmed that PI3K/Akt pathway could inhibit cell apoptosis by multiple processes to promote cell survival and tumourigenesis. The main processes included are as follows. Firstly, activation of Akt phosphorylates Bcl2-antagonist of cell death (BAD) on Ser136, a pro-apoptotic Bcl-2 related protein, to effectively block apoptosis [49, 50]. Secondly, caspase-9 acting as an initiator and an effector of apoptosis, could be phosphorylated on Ser196 by Akt, further inhibiting apoptosis and promoting cell survival [51, 52]. Thirdly, Akt contributes to the regulation of cell survival through transcriptional factors such as Forkhead, NF-κB and p53, which are responsible for pro- and anti-apoptotic genes [53–57]. Additionally, recent studies have reported that PI3K/Akt signal pathway also participates in VM formation by regulating the activity of membrane type 1 (MT1)-MMP, MMP-2 and the Ln-5β2 chain’s cleavage [35].

Membrane type 1-MMP and MMP-2 seem to be crucial to VM formation. MMP overexpression in human ovarian cancers helps form a vascular system lined by tumour cells [56]. PI3K/Akt mediates MT1-MMP’s function, and the latter could promote pro-MMP’s transition into its active form by coactions with the tissue inhibitor of MMP-2 (TIMP-2). Then, MMP-2 activation leads to Ln-5β2 chain cleavage into pro-migratory γ2 and γ3 fragments. These fragments are deposited in the ECM and participate in matrix plasticity, migration, invasion and VM formation [28, 33]. Researchers found that the poorly invasive melanoma cells inoculated in collagen matrix, after pre-treatment with highly invasive melanoma cells, could form tubular network structures along enriched Ln-5β2 chain tracks deposited in invasive malignant cells. The findings demonstrated that PI3K/Akt, MMPs and Ln-5β2 chain contribute to ECM remodelling and VM formation.

The inhibition of PI3K/Akt as well as related genes by gene knock-out or drugs intervention to promote cancer cell apoptosis has been the focus of treatment of tumour, like the application of siRNA, antisense oligonucleotides and small molecule inhibitors. Recently, antiangiogenesis therapies by inhibiting the PI3K/Akt signal pathway and MMPs activation have become another hot research topic in the field of anticancer therapy. Undoubtedly, the combination of anti-apoptosis and anti-VM formation by inhibiting the PI3K/Akt signal pathway may be an important target of treatment, and further researches are needed to find more effective drugs to suppress tumourigenesis.

**FAK, EphA2 and VE-cadherin**

Vascular endothelial-cadherin is one of the transmembrane proteins in the cadherin family and can be specifically expressed in endothelial cells [58]. VE-cadherin, an important adhesive protein, could promote homotypic cell interaction and play a significant role in vasculogenic activities [28]. Previous studies showed that VE-cadherin was expressed in aggressive melanoma cells but not in non-aggressive melanoma cells. Furthermore, VE-cadherin expression knockdown could inhibit VM formation [29], indicating that VE-cadherin may be associated with VM formation. VM-cadherin’s function in VM formation mainly acts by mediating EphA2 activities. EphA2 is a member of the ephrin-receptor family of PTKs and expresses in melanoma cells with a metastatic phenotype, which is crucial to angiogenesis [59, 60]. Microarray analysis showed that EphA2 and VE-cadherin were overexpressed in human aggressive melanoma cells but not in poorly aggressive melanoma cells [29, 31]. EphA2 and VE-cadherin are co-localized in sites with cell to cell contact. EphA2 knockdown could

---

Table 1 The major discoveries in the field of VM

| Classification       | Discovery of VM                                                                 | References        |
|----------------------|---------------------------------------------------------------------------------|-------------------|
| Structure            | Be lined by tumour cells rather than endothelial cells                          | [5]               |
|                      | Remodel the extracellular matrix                                                 | [28, 33, 38, 39]  |
| Histochemical stain  | Be positive PAS and negative CD31 staining                                      | [5]               |
| Epigenetics          | Express a multipotent, stem cell-like phenotype                                  | [113, 114, 118, 119] |
| Physiological function| Provide blood for tumour growth                                                | [5–7]             |
| Biological behaviour | Be associated with tumour invasion, metastasis                                  | [5, 43, 44]       |
| Clinical application | Be utilized for anticancer therapy                                              | [37, 133–138]    |
|                      | Be linked with poor prognosis and shorter 5-year survival                       | [22, 23, 43, 139–143] |
make cells lose their VM-forming abilities and lead to EphA2’s redistribution in the cell membrane, but it did not affect the positioning of VE-cadherin in cell-cell adhesion [58]. The interaction of EphA2 and its membrane-bound ligands will lead to EphA2’s phosphorylation, which could activate PIK-3 which promotes VM formation by MMPs and Ln-5 α2 chain [28, 29, 31, 50].

Focal adhesion kinase is a cytoplasmic tyrosine kinase linked with focal adhesion [58]. Relevant studies showed that FAK could regulate VM migration, invasion and formation in malignant tumours. When FAK is positioned on a membrane, it can activate extracellularly signal-regulated kinase1 and 2 (ERK1/2). ERK1/2’s phosphorylation further mediates MT1-MMP and MMP-2 through the PI3K signal pathway, and is thus involved in the ECM plasticity, migration, invasion and VM formation [38, 39].

TF, TFPI-1 and TFPI-2
Tissue factor (TF) is a transmembrane protein expressed in many cell types, including endothelial cells, smooth muscle cells, macrophages and solid tumours [61–64], and is related to vascular system development [65, 66]. TF pathway 1 (TFPI1) and TF pathway 2 (TFPI2) are
two coagulation pathway inhibitors, playing an important role in maintaining coagulation and anticoagulation system balances. A recent study demonstrated that TF, TFPI-1 and TFPI-2 were overexpressed in human invasive melanoma cells [67]. TF’s procoagulant function could be mediated by TFPI, which has been shown to have connections with VM network structure perfusion. Conversely, TF’s function cannot be inhibited by TFPI-2, but it is still regarded as an important VM formation factor. TFPI2, through interaction with MMP-2 and the plasmin-dependent way, was involved in endothelial-cell matrix remodelling. MMP-2 activity can be suppressed by inhibiting TFPI-2 expression. Additionally, several studies indicated that endothelial and tumour cell adhesion and migration could be regulated by matrix-related TFPI-2 activity. These findings suggested that TFPI-2 provides an essential mechanism for tumour progression and VM formation.

**VEGF, VEGFR1/2, hypoxia and HIF-1**

VEGF-A is secreted by almost all tumour cells and belongs to the angiogenic growth factor family associated with tumour angiogenesis. Binding VEGF-A to its ligand results in the dedifferentiation of endothelial cells into its precursor, stimulating vascular channel proliferation and formation in tumours, especially in avascular regions. Findings showed that, in melanoma, VM and angiogenesis were mediated by VEGF-A [68]. Relevant research demonstrated that, in ovarian cancer, expressions of VE-cadherin, EphA2 and MMPs could be up-regulated by VEGF-A, contributing to matrix plasticity and VM formation [69]. Silencing VEGF using siRNA could induce cell apoptosis and suppress cell proliferation and VM formation in osteosarcoma [70]. Brantley-Sieders [71] observed that VEGF expression and angiogenesis induced by VEGF were decreased through repressing EphA2 activity in breast cancer. The result also was obtained by another study on pancreatic islet cells.

The two tyrosine kinases receptors, VEGFR1 and VEGFR2, bind to VEGF and possess different characteristics. VEGFR1 has a higher VEGF binding ability but lower kinase activity compared to VEGFR2. VEGFR2 is linked with tumour angiogenesis [72, 73]. In the PI3K/Akt signal pathway, VEGFR1 activation was considered to participate in endothelial cell differentiation and angiogenesis. Melanoma cells failed to form capillary-like structures when VEGFR1 expression was inhibited using siRNA. This result further identifies the requirement of VEGFR1 for VM. However, inhibiting VEGFR2 expression by a specific inhibitor PTKI could not affect capillary-like structure formation, indicating that VM formation was mainly influenced by VEGFR1 activity rather than VEGFR2.

Growing tumours lack blood supply in a normal state. Hypoxia can stimulate tumour vessel structure formations [74] including angiogenesis and VM, which contributes to tumour metastasis. After hypoxia develops, HIF-1α and HIF-2α are generated by tumour cell activation. Then, HIF-1α activates VEGF expression by binding to the VEGF gene enhancer sequence, thereby resulting in VM formation [37, 75, 76]. Du *et al.* [20] showed that hypoxia promoted VM formation by inducing epithelial-mesenchymal transition (EMT) in ovarian cancer. In highly invasive gallbladder cancer cells, hypoxia could reportedly induce VM formation and increase HIF-1α expression. HIF-1α knockdown by siRNA significantly inhibited HIF-1α expression and VM channels under normoxia or hypoxic conditions [17]. Furthermore, in Ewing sarcoma tumours, HIF-1α activation was also shown to participate in VM formation. A recent study demonstrated that HIF-1α localization is not along the CD-31 zone of blood vessels but the VM networks [77], which was verified by hypoxia marker pimonidazole staining. Furthermore, severe hypoxia was found in tumour VM zones. These results suggested the relation between hypoxia and VM formation.

**Galectin 3**

Galectin-3 (Gal-3) is a β-galactosyl-binding lectin involved in biological functions including cell adhesion, cell migration, cell apoptosis and angiogenesis [78, 79]. Gal-3 is composed of three distinct domains: a glycine and proline-riched repeated collagen-like sequence domain, an NH2-terminal domain and a COOH-terminal carbohydrate recognition domain [80–82]. Gal-3 is widely expressed in various highly invasive tumours but not found in normal cells and most benign tumours. During benign melanoma’s progression to metastatic melanoma, Gal-3 was accumulated in tumour cell cytoplasm and in turn stimulated tumour cells to transform into higher invasive types and resulted in vessel formation and distant metastasis. Mourad-Zeidan AA [83] showed that Gal-3 silencing using shRNA made melanoma cells lose their invasiveness abilities and channel structure formation on collagen in *vitro*. Gal-3 mediated the expression of many genes, such as VE-cadherin, interleukin-8 (IL-8) and MMP-2, which are confirmed to contribute to VM formation. Silencing Gal-3 expression inhibited VE-cadherin and IL-8 promoter activities, mainly owing to increased recruitment of early growth response-1 (EGR-1), a transcription factor participating in maintaining differentiation processes in normal tissues. EGR-1 overexpression repressed VE-cadherin, IL-8 and their promoter activities, while Gal-3 expression blocked EGR-1 binding to gene promoter and induced VM formation in tumour tissues.

**Cyclic adenosine monophosphate and nodal**

Cyclic adenosine monophosphate (cAMP), a second messenger regulating cell growth and differentiation, is generated by activated adenylyl cyclase acting on ATP. Several studies have proven that in aggressive melanoma, cAMP increase resulted in VM formation inhibition through multiple signalling pathways. First, cAMP stimulates PKA-independent activation of Epac/Rap1 pathway to restrain vessel-like channel structure formation. Additionally, cAMP helps inhibit MMP-2 and MT1-MMP expression by suppressing ERK1/2 to block VM formation. A recent study found that forskolin resulted in increased cAMP that strongly restrained VM formation by activation of Epac/Rap1, and inhibition of ERK1/2 and PI3K/Akt functional activation [84].

Nodal belongs to one transformation growth factor β (TGF-β) superfamily and plays an important role in maintaining tumourigenicity and melanoma progression. Nodal and Notch receptor were implicated in stem cell-associated plasticity development and up-regulation of Nodal expression, which was found in invasive melanoma cells [85]. Topczewska *et al.* [86] demonstrated that activating Nodal contributed to VM formation by increasing VE-cadherin expression.
Cyclooxygenase (COX), a necessary enzyme in prostaglandins synthesis, consists of the isoenzymes COX-1 and COX-2. A housekeeping enzyme, it mainly existed in blood vessels, stomach and other tissues. It is widely regarded as participating in the body’s normal physiological processes and protection functions, such as maintaining gastrointestinal mucosa integrity and platelet function adjustment. The latter is an inducible type mainly produced by inducting various pathophysiological stimuli including chemical, physical and biological factors, thus participating in inflammatory reactions by promoting prostaglandins synthesis. As a rate-limiting enzyme of prostaglandin E2 (PGE2), COX2 shows no expression or low expression in normal tissue cells, but it is highly expressed in a variety of epithelial tumours due to environment induction. Basu et al. [87] found that human invasive breast cancer cells with high COX-2 expression were observed to form VM in three-dimensional culture, while breast cancer cells with lower COX2 expression failed to form vessel-like channel structures. COX-2 knockdown using siRNA in highly invasive tumours markedly restrained vessel structure formation, indicating that COX-2 may contribute to VM formation regulation. Additionally, COX-2 resulted in the up-regulation of VEGF expression by activating PKC in various tumour cells, thereby promoting VM formation [88]. COX-2 can also increase PGE-2 expression, and both are overexpressed in invasive tumours and associated with tumour proliferation, apoptosis, invasion and angiogenesis by regulating the prostanoid receptor (EP1-4) family [28]. Binding PGE2 with its ligand EP3 could activate ERK1/2 by PKC to mediate VM formation. Therefore, COX2 may play an important role in VM formation. Its specific mechanisms need further research.

Other relevant molecule mechanisms

Inhibitors of DNA binding 2
Inhibitors of DNA binding 2 (Id2) is a member of the helix-loop-helix (HLH) protein family that participates in many cellular processes, including cell proliferation, differentiation, cell cycle regulation and tumourigenesis [89–91]. In highly aggressive uveal melanoma cells, Su [92] reported that Id2 knockdown using RNA interference could abolish VM formation by down-regulating VE-cadherin expression. It also affects cellular stability, indicating that Id2 may be vital to vessel-like structure formation.

Migration-inducing protein 7
Migration-inducing protein 7 (Mig-7), a cysteine-rich protein, plays an important role in tumour migration and circulation. There is evidence showing that Mig-7 is overexpressed in highly aggressive melanoma cells with VM but not in poorly aggressive melanoma without VM [93]. Mig-7 overexpression was capable of increasing Ln-5 and laminin chain domain III fragments, thus promoting tumour cell migration, metastasis and VM formation.

Caspase-3
Caspase-3 is implicated in cell apoptosis [94, 95], proliferation [96–98], migration [99–101] and differentiation [102–104] in normal tissues and tumours. In melanoma metastases, active caspase-3 expression was observed [105]. Liu et al. [106] revealed that downregulating caspase-3 by siRNA helped inhibit tumour migration, invasion and VM, suggesting that caspase-3 is related to tube-like structure formation. Additionally, it has been pointed out that caspase-3 mutations are not uncommon in malignant cancers. Chen et al. [107] showed that genetic variation in caspase-3 is associated with an increased risk of squamous cell carcinoma of the head and neck (SCCHN). Most of the caspases mutations detected in human cancers showed attenuate apoptosis compared with the wild-type caspases, indicating a significant role of the inhibition of apoptosis by caspases mutations in tumourigenesis [108]. But it seems that there are no correlative studies on the relativity between caspases mutations and tumourigenesis induced by VM. Therefore, considerable studies about caspases and VM are important, and contribute to finding an effective gene therapy or targeting therapy for tumours.

Endothelin-1
Endothelin (ET)-1 is considered a practical tumour marker, the secretion of which is increased in a variety of pathological conditions and cancer patients. In primary and metastatic melanoma cell lines, the activation of a G-protein coupled receptor by ET-1 could markedly result in increased VEGFR-3, MAPK and ATK, thereby significantly promoting tumour cell invasion and VM formation [109]. Furthermore, the ETBR antagonist repressed VEGF-C/VEGFR-3 axis activation and prevented tumour growth and VM formation, suggesting that ET-1/ETBR might provide an essential therapeutic target for melanoma treatment by VEGFR-3.

Bone morphogenetic protein 4
Bone morphogenetic protein 4 (BMP4) is another tumour migration and invasion regulator. Reducing BMP4 activity in melanoma cells reduced VE-cadherin and EphA2 expression and failed to promote tubular structure formation [110].

Human chorionic gonadotropin
Human chorionic gonadotropin (hCG) is reportedly capable of inducing VM formation in ovarian cancer cell line OVCAR-3. hCG expression is higher under hypoxia compared to normoxia. Inhibiting HIF-1α expression using siRNA resulted in significantly decreased hCG expression in OVCAR-3. Treating OVCAR-3 with 5000 mU/ml hCG led to the induction of vessel-like networks lined by tumour cells and markedly enhanced vascular marker expression even under normoxia [21].
CSC, EMT and VM

Tumours contain a small portion of cells capable of self-renewal and multiple potential differentiation called cancer stem cells (CSCs). Lapidot et al. [111] firstly demonstrated CSC, and they were subsequently observed in several solid tumours, including breast cancer [112], glioblastoma [113], colon cancer [114], melanoma [115, 116], ovarian cancer [117, 118], prostate cancer [119] and pancreatic cancer [120]. More evidence shows that CSCs are capable of differentiating towards tumour and endothelial lineages [121, 122], possessing both phenotypes. Additionally, CSCs are associated with tumour invasion and metastasis, and many CSC markers were involved in these processes, such as ALDH1 [123], CD44+ [124] and FRMD4A [125]. Hermann et al. [120] also showed that CSCs phenotypes of CD133/CXCR4 in pancreatic cancer are related to tumour metastasis and tumourigenesis, and CSCs are thus classified into two types: invasive CSCs crucial in tumour invasion and metastasis, and stationary CSCs associated with tumourigenesis.

Recently mounting studies implicated CSCs in VM formation. Mirshahi et al. [126] found that adherent bone marrow stromal cells derived from CD133+/CD34+ stem cells from acute leukaemia patients were able to secrete more insulin growth factor-1 and stromal cell-derived factor-1 (SDF-1) alph, and could result in the formation of capillary-like structures (‘VM’) on Matrigel. Furthermore, there is evidence showing that oral SCC, TRA-1-60+/beta6+ stem cells were capable of producing vascular-like structures in vivo. Additionally, in melanoma, it was shown that some phenotypes generally expressed in epithelial or endothelial cells were observed to express in VM-engaging tumour cells [127]. Ricci-Vitiani et al. [121] found that in glioblastoma, the vessels in tumour xenografts generated by orthotopic or subcutaneous injection of glioblastoma stem-like cells in immunocompromised mice were made up of human endothelial cells, which indicated CSCs’ differentiation potential along endothelial lineage and their involvement in VM formation.

Epithelial-mesenchymal transition is a dedifferentiation process that plays an integral role in tumour progression. By epithelial cells transitioning into mesenchymal cells, EMT acquired mesenchymal features and lost epithelial phenotypes, mainly including epithelial marker downregulation, mesenchymal marker upregulation and cell polarity loss. EMT is reportedly involved in tumour invasion and metastasis. Cadherin switching, an important EMT marker associated with the EMT differentiation process, contains E-cadherin expression loss and N-cadherin gains. Recent studies show that transcription factors related to EMT are upregulated in VM-forming tumour cells. As a main EMT-mediated process regulator, Twist reportedly promotes breast cancer metastasis into distant regions [128]. Similarly, in HCC, Zhao et al. [129] found that Twist1 could down-regulate E-cadherin expression and contribute to MMP activation, particularly in MMP2 and MMP9, thus inducing HCC invasion. Interestingly, Twist2 had no effect in HCC invasion and metastasis, and specific mechanisms need further research. Snail and Slug are two other transcription factors able to inhabit E-cadherin transcription and stimulate tumour cell migration by binding to E-boxes present in human E-cadherin promoter [130–132]. A recent study demonstrated that EMT was implicated in VM formation. It showed that the poorly differentiated cell line SK-Hep-1 with mesenchymal features (high invasiveness and expressing Vimentin, with no E-cadherin) was capable of forming VM in vitro. The well-differentiated cell line HepG2 failed to form VM, and no correlation was found between intrinsic VM ability and stemness gene expression [133]. In colorectal carcinoma, Liu et al. [134] showed that ZEB1 expression was upregulated in VM-positive samples compared with VM-negative samples, while it occurred concurrently with EMT traits. Additionally, ZEB1 knockdown in tumour cells abolished VM formation, led to epithelial phenotype restoration, and evidently repressed tumour migration and invasion. Moreover, ZEB1 down-expression resulted in decreased VE-cadherin expression and Fk-1, which went against VM formation. This means EMT contributes to VM formation and maybe provides a therapeutic target for anti-angiogenesis therapy.

With increasing studies on CSC’s origin, more evidence indicated that differentiated tumour cell stemness can be acquired by EMT induction, which may become a new CSC origin mechanism. Xia et al. [135] reported that miR-200a could regulate EMT by targeting ZEB2 and stem-like transition by β-catenin signalling in nasopharyngeal carcinoma cells. Stable miR-200a knockdown stimulated EMT phenotypes and led to stem cell characteristics, including sphere formation capacity, CD133(+) side population, stem cell marker expression, and in vivo tumourigenicity in nude mice. Stable miR-200a overexpression had the opposite result. Fang et al. [136] showed that Twist2 overexpressed in breast carcinoma cells promoted stem cell marker expression, increased stem-like cells’ self-renewal abilities, and contributed to tumour progression. It was also found that epithelial breast cancer cells undergoing EMT acquired a CD24(-)/CD44(+) phenotype consistent with breast CSCs. They also acquired breast CSC features, including epithelial tumour reestablishing capacity, potent tumourigenicity and increased resistance to drugs and radiation [137]. Furthermore, in mammary tissue, Mani et al. [138] observed that mesenchymal traits and stem-cell marker expressions could be obtained by EMT induction in immortalized human mammary epithelial cells (HMCLs). Moreover, stem-like cells isolated from HMCL cultures or mammary carcinomas could express EMT markers. The relationship between EMT and CSC has also been found in HNSCC [139] and colorectal [140]. Additionally, the hypoxia microenvironment is considered an important factor in regulating VM formation by maintaining stemness and EMT induction. These findings widely suggested that CSC may be involved in VM formation by EMT induction.

VM and cancer therapeutics

Anti-angiogenic treatment is widely accepted as an effective anticancer therapy. Common anti-angiogenic drugs like angiostatin and endostatin play a role mainly by reducing endothelial cell proliferation or inducing endothelial cell apoptosis, but they have little effect on vessel-like structures lined by tumour cells. Furthermore, when blood vessel density is reduced due to anti-angiogenic therapy, it may lead to hypoxia. Subsequently, oxygen and nutrient deficiency as a compensatory stimulus will contribute to VM formation and indirectly promote tumour progression. Moreover, several of these drugs have a
VM and prognosis of human cancer patients

Vasculogenic mimicry provides adequate blood supply for various malignant tumours to promote tumour invasion and metastasis. Subsequent studies showed that VM was significantly linked with poor prognosis for patients with aggressive tumours [22, 23, 43, 147]. Poor 5-year survival was observed in some VM-forming aggressive cancers, including melanoma, colorectal cancer, lung cancer, sarcomas and hepatic cancer. Cao et al. [148] reported that the relative 5-year survival risk of VM-positive patients was significantly higher than with VM-negative cases. Higher VM rates and worse 5-year survival rates were observed in melanoma patients with metastasis compared to patients with primary melanoma, indicating that VM was able to promote tumour metastasis and poor prognosis in malignant cancer patients. In 168 cases of laryngeal squamous cell carcinoma (LSCC), Lin et al. [149] demonstrated that VM formation in LSCC cells enhanced tumour invasion and metastasis potential. Additionally, a VM positive rate was strongly related to tumour stage, grade and metastasis, and miR-200a expression in VM-positive ovarian cancer showed low levels. Furthermore, the overall survival (OS) of patients with low miR-200a expression and/or positive VM formation was significantly shortened by evaluating Kaplan–Meier curves [150]. The finding suggested that VM and miR-200a might play a vital role in ovarian cancer’s progression and prognosis. Recently, Wang et al. [151] revealed that the median survival rate of VM-forming patients is markedly shorter than in patients without VM, so VM may be a prognostic factor for post-operative survival in patients with glioblastoma. However, several studies demonstrated that VM had no significantly statistical association with tumour prognosis, although shorter survival was observed in VM-positive patients [43, 127, 152, 153]. Therefore, VM’s influence on cancer patients’ OS remains controversial. VM is widely considered, though, to provide predictive signals for cancer patient prognosis. Further study is needed to analyse the precise relationship between VM and human cancer patient prognosis, contributing to better individual therapy selection for cancer patients by predicting tumour progression early.

Conclusion

As a brand-new tumour vascular pattern, VM describes the functional ability of aggressive cancer cells to express a multipotent, stem cell-like phenotype and form ECM-rich and patterned vasculogenic-like networks to provide adequate blood supply for tumour growth in a three-dimensional matrix. VM with positive PAS and negative CD31 is linked by tumour cells and independent of epithelial cells. As a unique perfusion way, VM has been observed in a variety of aggressive tumours. Many molecule mechanisms, especially VE-cadherin, EphA2, PI3K, MMPs, VEGFR1 and HIF-1a, are involved in tumour migration, invasion, and VM formation. However, their specific roles in VM still remain unclear. Furthermore, CSC and EMT are also shown to participate in VM formation. Also, CSC may be implicated in VM formation by EMT induction. There is increasing evidence showing that VM and VM density levels are linked with poor prognosis and shorter 5-year survival in cancer patients. Ordinarily, VM-forming aggressive tumours have the increased potential to metastasize to distant organs, therefore, predicting cancer progression in advance may be extremely important. Currently, many VM-related strategies are utilized for anticancer treatment by preventing VM formation, and many drugs shows an effective outcome in inhibiting it. More therapies targeting VM need to be attempted in experimental and clinical research. VM inhibitors combining with anti-angiogenic therapies may be a promising therapeutic target in anti-tumour therapy.
Acknowledgements

A grant from the Natural Science Foundation of Shandong Province (No. ZR2012HM095) supported this study.

Conflicts of interest

The authors declare that we have no conflict of interest.

References

1. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298–307.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57–70.
4. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011; 146: 873–87.
5. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155: 739–52.
6. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000; 156: 361–81.
7. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000; 406: 536–40.
8. Paulis YW, Soetekouw PM, Verheul HM, et al. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 2010; 1806: 18–28.
9. Cao Z, Yu D, Fu S, et al. Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicol Lett. 2013; 218: 174–85.
10. Hess AR, Margayyan NV, Seftor EA, et al. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn. 2007; 236: 3283–96.
11. Mei J, Jia YW, Cai XS. Vascular channel formation by osteosarcoma cells in vitro: vasculogenic mimicry. Chin-German J Clin Oncol. 2003; 2: 237–9.
12. van der Schaff DW, Seftor RE, Seftor EA, et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst. 2004; 96: 1473–7.
13. Sun T, Zhao M, Zhao XL, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatolology. 2010; 51: 545–56.
14. Sharma N, Seftor RE, Seftor EA, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate. 2002; 50: 189–201.
15. Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem. 2005; 53: 997–1002.
16. El Hallani S, Boisselier B, Pégilion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010; 133: 973–82.
17. Sun W, Shen ZY, Zhang H, et al. Overexpression of HIF-1α in primary galbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep. 2012; 27: 1990–2002.
18. Fujimoto A, Ondera H, Mori A, et al. Tumour plasticity and extravascular circulation in ECV304 human bladder carcinoma cells. Anticancer Res. 2006; 26: 59–69.
19. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol. 2001; 158: 1279–88.
20. Du J, Sun B, Zhao X, et al. Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. Gynecol Oncol. 2014; 133: 57–63.
21. Su M, Wei W, Xu X, et al. Role of hOG in vasculogenic mimicry in OVCAR-3 ovarian cancer cell line. Int J Gynecol Cancer. 2011; 21: 1366–74.
22. Wu S, Yu L, Cheng Z, et al. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 346–52.
23. Liu WB, Xu GL, Jia WD, et al. Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med Oncol. 2011; 28: S228–38.
24. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002; 62: 560–6.
25. Cai XS, Jia YW, Mei J, et al. Tumor blood vessels formation in osteosarcoma: vasculogenic mimicry. Chin Med J (Engl). 2004; 117: 94–8.
26. Jiang J, Liu W, Guo X, et al. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKB2-dependent neovascularization on gastric cancer. Oncogene. 2011; 30: 4498–508.
27. Li M, Gu Y, Zhang Z, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res. 2010; 16: 259–66.
28. Kirschmann DA, Seftor EA, Hardy KM, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res. 2012; 18: 2726–32.
29. Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA. 2001; 98: 8018–23.
30. Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther. 2006; 5: 228–33.
31. Hess AR, Seftor EA, Gardner LM, et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res. 2001; 61: 3250–5.
32. Margayyan NV, Strizzi I, Abbott DE, et al. EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther. 2009; 8: 279–88.
33. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1 matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res. 2001; 61: 6322–7.
34. Seftor RE, Seftor EA, Kirschmann DA, et al. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and...
75. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000; 59: 47–53.

76. Jones MK, Szabo IL, Kawanaka H, et al. von Hippel Lindau tumor suppressor and HIF-1α: new targets of NSAIIDs inhibition of hypoxia-induced angiogenesis. FASEB J. 2002; 16: 264–6.

77. Sun B, Zhang D, Zhang S, et al. Hypoxia influences vascular mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett. 2007; 249: 188–97.

78. Lau KS, Dennis JW. N-Glycans in cancer progression. Glycobiology. 2008; 18: 750–60.

79. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycogen J. 2004; 19: 527–35.

80. Cassarino DS, Derienzo DP, Barr RJ. Krezel L, Luo H, Chen Z, Jin H, Basu GD, Liang WS, Stephan DA, Topczewska JM, Postovit LM, Margaryan NV, Seftor EA, et al. Cyclooxygenase-2 up-regulates vascular channel formation by human melanoma cells: role of helix-loop-helix I02 (inhibitor of DNA binding 2). Graefe's Arch Clin Exp Ophthalmol. 2009; 247: 411–9.

81. Petty AP, Garman KL, Winn WD, et al. Over-expression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation. Am J Pathol. 2007; 170: 1763–80.

82. Yoshii T, Fukumori T, Honjo Y, et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem. 2002; 277: 6852–7.

83. Mourad-Zeidan AA, Melnikova VO, Wang H, et al. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol. 2008; 173: 1839–52.

84. Lissitzky JC, Parriaux D, Ristorcelli E, et al. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro. Cancer Res. 2009; 69: 802–9.

85. Postovit LM, Margaryan NV, Settor EA, et al. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res. 2008; 21: 548–57.

86. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med. 2006; 12: 925–32.

87. Basu GD, Liang WS, Stephan DA, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res. 2006; 8: R69.

88. Luo H, Chen Z, Jin H, et al. Cyclooxygenase-2 up-regulates vascular endothelial growth factor via a protein kinase C pathway in non-small cell lung cancer. J Exp Clin Canc Res. 2011; 30: 6–10.

89. Andres-Barquin PJ, Hernandez MC, Israel MA. Id genes in nervous system development. Histol Histopathol. 2000; 15: 603–18.

90. Benezza R. Role of Id proteins in embryonic and tumor angiogenesis. Trends Cardiovasc Med. 2001; 11: 237–41.

91. Ruzinova MB, Benezza R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003; 13: 410–8.

92. Su F, Li B, Wang J, et al. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix I02 (inhibitor of DNA binding 2) expression. J Exp Clin Canc Res. 2011; 30: 6.

93. Petsky AP, Garman KL, Winn WD, et al. Over-expression of carcinoma and embryonic cytotrophoblast cell-specific Mig-7 induces invasion and vessel-like structure formation. Am J Pathol. 2007; 170: 1763–80.

94. Crawford ED, Seaman JE, Barber AE 2nd, et al. Conservation of caspase substrates across metazoans suggests hierarchical importance of signaling pathways over specific targets and cleavage site motifs in apoptosis. Cell Death Differ. 2012; 19: 2040–8.

95. Hyman BT, Yuan J. Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology. Nat Rev Neurosci. 2012; 13: 395–406.

96. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 2002; 419: 395–9.

97. Su H, Bidere N, Zheng L, et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science. 2005; 307: 1465–8.

98. Van Raam BJ, Salvesen GS. Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim Biophys Acta. 2012; 1824: 113–22.

99. Watanabe Y, Akaite T. Possible involvement of caspase-like activity in maintenance of cytoskeleton integrity. J Cell Physiol. 1999; 179: 45–51.

100. Antonopoulos C, Cumberbatch M, Dearman RJ, et al. Functional caspase-1 is required for Langerhans cell migration and optimal contact sensitization in mice. J Immunol. 2001; 166: 3672–7.

101. Helfer B, Boswell BC, Finlay D, et al. Caspase-8 promotes cell motility and calpain activity under nonapoptotic conditions. Cancer Res. 2006; 66: 4273–8.

102. Warso MA, Maniotis AJ, Chen X, et al. Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res. 2001; 7: 473–7.

103. Thies A, Mangold U, Moli I, et al. Positive loops and networks as a prognostic indicator in cutaneous malignant melanoma. J Pathol. 2001; 195: 537–42.

104. Van Beurden A, Schmitz RF, van Dijk CM, et al. Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. Melanoma Res. 2012; 22: 424–9.

105. Woenckhaus G, Giebel J, Failing K, et al. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression? J Pathol. 2003; 201: 278–87.

106. Liu YR, Sun B, Zhao XL, et al. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res. 2013; 23: 243–53.

107. Chen K, Zhao H, Hu Z, et al. CASP3 polymorphisms and risk of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008; 14: 6343–9.

108. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of CASP3 gene in human cancers. Hum Genet. 2004; 115: 112–5.

109. Spinella F, Caprara V, Di Castro V, et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med. 2013; 91: 395–405.

110. Rothhammer T, Bataille F, Spruss T, et al. Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene. 2007; 26: 4158–70.

111. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645–8.

112. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983–8.

113. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396–401.

114. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106–10.

115. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005; 65: 9328–37.
